Zenas Biopharma, INC. (ZBIO) — SEC Filings

Overview

Zenas Biopharma, INC. (ZBIO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 424B5 filed on Mar 30, 2026: Zenas BioPharma, Inc. filed a 424B5 prospectus supplement on March 30, 2026, related to its previously filed registration statement. This filing is part of the process for offering securities, though specific details on the number of shares or price are not included in this document excerpt.

Sentiment Summary

Across 32 filings, the sentiment breakdown is: 1 bearish, 31 neutral. The dominant filing sentiment for Zenas Biopharma, INC. is neutral.

Filing Type Overview

Zenas Biopharma, INC. (ZBIO) has filed 2 4, 3 424B5, 2 FWP, 13 8-K, 3 10-Q, 1 DEF 14A, 1 10-K, 3 SC 13G, 2 SC 13D, 1 S-1/A, 1 S-1 with the SEC between Aug 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (32)

• 4 Filing — 4 · Apr 2, 2026
• 4 Filing — 4 · Apr 1, 2026
• 424B5 Filing — 424B5 · Mar 30, 2026
• Zenas BioPharma Files Prospectus Supplement — 424B5 · Mar 30, 2026 Risk: low
  Zenas BioPharma, Inc. filed a 424B5 prospectus supplement on March 30, 2026, related to its previously filed registration statement. This filing is part of the
• Zenas BioPharma Files Free Writing Prospectus — FWP · Mar 27, 2026 Risk: medium
  Zenas BioPharma, Inc. filed a Free Writing Prospectus (FWP) on March 27, 2026, related to its securities. The filing, with SEC Accession Number 0001104659-26-03
• Zenas BioPharma Files Free Writing Prospectus — FWP · Mar 27, 2026 Risk: medium
  Zenas BioPharma, Inc. filed a Free Writing Prospectus (FWP) on March 27, 2026. This filing is related to a registration statement with file number 333-290777. T
• Zenas BioPharma Files Prospectus for Securities Offering — 424B5 · Mar 26, 2026 Risk: medium
  Zenas BioPharma, Inc. filed a 424B5 prospectus on March 26, 2026, detailing an offering of securities. The filing, with SEC Accession Number 0001104659-26-03524
• Zenas BioPharma Announces Board and Executive Changes — 8-K · Dec 15, 2025 Risk: medium
  Zenas BioPharma, Inc. announced on December 10, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departur
• Zenas BioPharma Files 8-K on Financials — 8-K · Nov 12, 2025 Risk: low
  Zenas BioPharma, Inc. filed an 8-K on November 12, 2025, reporting on its results of operations and financial condition. The filing includes financial statement
• Zenas BioPharma Files 8-K Report — 8-K · Oct 27, 2025 Risk: low
  On October 27, 2025, Zenas BioPharma, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a R
• Zenas BioPharma Files 8-K: Agreements, Financials, Equity Sales — 8-K · Oct 8, 2025 Risk: medium
  On October 7, 2025, Zenas BioPharma, Inc. entered into a material definitive agreement. The company also reported on its results of operations and financial con
• Zenas BioPharma Completes Asset Acquisition from 03 Life Sciences — 8-K · Sep 2, 2025 Risk: medium
  On September 2, 2025, Zenas BioPharma, Inc. announced the completion of its acquisition of certain assets from 03 Life Sciences. This transaction involved a mat
• Zenas BioPharma Files 8-K on Financials — 8-K · Aug 12, 2025 Risk: low
  Zenas BioPharma, Inc. filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition. The filing also includes financial statem
• Zenas BioPharma's Losses Widen Amid Soaring R&D, Cash Drains — 10-Q · Aug 12, 2025 Risk: high
  Zenas BioPharma, Inc. (ZBIO) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $85.796 million, up from $65.777 milli
• Zenas BioPharma Announces Board and Executive Changes — 8-K · Jun 12, 2025 Risk: medium
  Zenas BioPharma, Inc. announced on June 10, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of
• Zenas BioPharma Files 8-K Report — 8-K · Jun 4, 2025 Risk: low
  On June 4, 2025, Zenas BioPharma, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No spe
• Zenas BioPharma Files 8-K on Operations and Financials — 8-K · May 15, 2025 Risk: low
  On May 15, 2025, Zenas BioPharma, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well a
• Zenas BioPharma Files 10-Q, Details Xencor & Viridian Ties — 10-Q · May 15, 2025 Risk: medium
  Zenas BioPharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company's primary business is in pharmaceutical preparations. Key relationships a
• Zenas BioPharma Files Annual Proxy Statement — DEF 14A · Apr 28, 2025 Risk: low
  Zenas BioPharma, Inc. filed a DEF 14A proxy statement on April 28, 2025, for its annual meeting on June 10, 2025. The filing concerns the company's governance a
• Zenas BioPharma Files 2024 10-K, Reports $81M R&D Spend — 10-K · Mar 11, 2025 Risk: medium
  Zenas BioPharma, Inc. filed its 2024 10-K on March 11, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, inco
• Zenas BioPharma Files 8-K on Financials — 8-K · Feb 5, 2025 Risk: low
  Zenas BioPharma, Inc. filed an 8-K on February 5, 2025, reporting on its results of operations and financial condition. The filing includes financial statements
• Zenas BioPharma Files 8-K — 8-K · Dec 2, 2024 Risk: low
  Zenas BioPharma, Inc. filed an 8-K on December 2, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain
• Zenas BioPharma Files 8-K on Operations and Financials — 8-K · Nov 12, 2024 Risk: low
  Zenas BioPharma, Inc. filed an 8-K on November 12, 2024, reporting on its results of operations and financial condition. The filing also includes financial stat
• Zenas BioPharma Q3 2024: Assets $81.2M, Liabilities $1.8M — 10-Q · Nov 12, 2024 Risk: medium
  Zenas BioPharma, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $81.24 million and total liabilities of $1.7
• SC 13G Filing — SC 13G · Nov 12, 2024
• SC 13G Filing — SC 13G · Oct 21, 2024
• SC 13G Filing — SC 13G · Sep 25, 2024
• Longitude Capital Discloses Stake in Zenas BioPharma — SC 13D · Sep 23, 2024 Risk: medium
  On September 23, 2024, Longitude Capital Partners IV, LLC, along with related entities and individuals including Juliet Tammenoms Bakker and Patrick G. Enright,
• Enavate Sciences Files SC 13D for Zenas BioPharma — SC 13D · Sep 23, 2024 Risk: medium
  On September 23, 2024, Enavate Sciences GP, LLC, through Zebra Aggregator, LP, filed an SC 13D, indicating a change in beneficial ownership of Zenas BioPharma,
• Zenas BioPharma Files 8-K for Bylaws and Financials — 8-K · Sep 16, 2024 Risk: low
  Zenas BioPharma, Inc. filed an 8-K on September 16, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The company,
• Zenas BioPharma Files S-1/A for IPO — S-1/A · Sep 6, 2024 Risk: medium
  Zenas BioPharma, Inc. filed an S-1/A amendment on September 6, 2024, for its initial public offering. The company, previously known as Zenas BioPharma (Cayman)
• Zenas BioPharma Files S-1 for Public Offering — S-1 · Aug 22, 2024 Risk: medium
  Zenas BioPharma, Inc. filed an S-1 registration statement with the SEC on August 22, 2024, indicating its intent to offer securities to the public. The company,

Related Companies

ZENA · ZENAS

Frequently Asked Questions